Braden Millan1, Michael Laffin2, Karen Madsen3. 1. Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. 2. Department of Medicine, CEGIIR: Center of Excellence for Gastrointestinal Inflammation and Immunity Research, 7-142 Katz Group Center, University of Alberta, Edmonton, AB, Canada. 3. Department of Medicine, CEGIIR: Center of Excellence for Gastrointestinal Inflammation and Immunity Research, 7-142 Katz Group Center, University of Alberta, Edmonton, AB, Canada. kmadsen@ualberta.ca.
Abstract
PURPOSE OF REVIEW: Fecal microbiota transplantation (FMT) has been established as standard of care in the treatment of antibiotic refractory Clostridium difficile infection (RCDI). This review examines the current evidence that exists to support the use of FMT in the treatment of human disease beyond C. difficile infection. RECENT FINDINGS: Beneficial effects of FMT have been described in case series or small prospective trials on a wide spectrum of conditions, including inflammatory bowel disease, functional gastrointestinal disorders, non-alcoholic steatohepatitis, alcoholic hepatitis, hepatic encephalopathy, and neuropsychiatric conditions, and in limiting antibiotic-resistant bacterial infections. Each of these proposed indications for FMT is associated with an underlying dysbiosis of the gastrointestinal microbiota and generally a clinical response is linked with a restoration of the gut microbiota. The potential of fecal microbial transplantation to alter disease course shows promise but further large-scale studies are necessary to understand limitations as well as how best to utilize this therapy.
PURPOSE OF REVIEW: Fecal microbiota transplantation (FMT) has been established as standard of care in the treatment of antibiotic refractory Clostridium difficileinfection (RCDI). This review examines the current evidence that exists to support the use of FMT in the treatment of human disease beyond C. difficileinfection. RECENT FINDINGS: Beneficial effects of FMT have been described in case series or small prospective trials on a wide spectrum of conditions, including inflammatory bowel disease, functional gastrointestinal disorders, non-alcoholic steatohepatitis, alcoholic hepatitis, hepatic encephalopathy, and neuropsychiatric conditions, and in limiting antibiotic-resistant bacterial infections. Each of these proposed indications for FMT is associated with an underlying dysbiosis of the gastrointestinal microbiota and generally a clinical response is linked with a restoration of the gut microbiota. The potential of fecal microbial transplantation to alter disease course shows promise but further large-scale studies are necessary to understand limitations as well as how best to utilize this therapy.
Authors: Paul Moayyedi; Michael G Surette; Peter T Kim; Josie Libertucci; Melanie Wolfe; Catherine Onischi; David Armstrong; John K Marshall; Zain Kassam; Walter Reinisch; Christine H Lee Journal: Gastroenterology Date: 2015-04-07 Impact factor: 22.682
Authors: Jasmohan S Bajaj; Zain Kassam; Andrew Fagan; Edith A Gavis; Eric Liu; I Jane Cox; Raffi Kheradman; Douglas Heuman; Jessica Wang; Thomas Gurry; Roger Williams; Masoumeh Sikaroodi; Michael Fuchs; Eric Alm; Binu John; Leroy R Thacker; Antonio Riva; Mark Smith; Simon D Taylor-Robinson; Patrick M Gillevet Journal: Hepatology Date: 2017-10-30 Impact factor: 17.425
Authors: Janneke E Stalenhoef; Elisabeth M Terveer; Cornelis W Knetsch; Peter J Van't Hof; Imro N Vlasveld; Josbert J Keller; Leo G Visser; Eduard J Kuijper Journal: Open Forum Infect Dis Date: 2017-03-13 Impact factor: 3.835
Authors: Yanling Wei; Jun Yang; Jun Wang; Yang Yang; Juan Huang; Hao Gong; Hongli Cui; Dongfeng Chen Journal: Crit Care Date: 2016-10-18 Impact factor: 9.097
Authors: Heekuk Park; Michael R Laffin; Juan Jovel; Braden Millan; Jae E Hyun; Naomi Hotte; Dina Kao; Karen L Madsen Journal: Gut Microbes Date: 2019-03-13
Authors: Srinivasa Nithin Gopalsamy; Amy Sherman; Michael H Woodworth; Joseph D Lutgring; Colleen S Kraft Journal: Infect Control Hosp Epidemiol Date: 2018-01-18 Impact factor: 3.254